Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
04 12월 2013 - 9:45PM
Marketwired
Sirona Biochem Announces Signing of Deal for Collaboration with
Bloom Burton & Co.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec 4, 2013) -
Sirona Biochem Corp. (TSX-VENTURE:SBM)(OTCQX:SRBCF) and Bloom
Burton & Co. ("Bloom Burton") announce the signing of a joint
venture to conduct collaborative research to develop and
commercialize new therapeutics in the areas of inflammation and
infectious disease.
Sirona and Bloom Burton will identify and design numerous
different anti-inflammatory and anti-infective compounds. Sirona
will be responsible for the chemistry, using its proprietary
expertise in fluorination technology. Bloom Burton will be
responsible for financing, clinical validation and
commercialization of the compounds. At present, there are unmet
market needs in the areas of rare or neglected inflammatory
diseases and bacterial resistance. With the former, often
overlooked and the latter, an emerging threat, the collaboration
between Sirona and Bloom Burton will endeavor to help minimize the
medical gap by maximizing on each of the companies' core
competencies.
"We are extremely excited to be working alongside Bloom Burton,
a national leader in healthcare-specialized investment banking"
said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will
combine the best of our expertise to develop the compounds,
expanding our product portfolio and delivering innovative solutions
in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry
platform and we are excited to explore opportunities in two
important and unmet therapeutic indications," said Brian Bloom,
President of Bloom Burton & Co. "In addition to capital
raising, advisory, equity research and direct investments, Bloom
Burton is excited to expand its activities to include company
creation and incubation, which should create value for Sirona
shareholders and our firm."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in
healthcare. Bloom Burton has an experienced team of medical,
scientific, pharmaceutical, legal and capital markets professionals
who perform a deeper level of diligence, which combined with a
creative and entrepreneurial culture, leads to the right monetizing
events for companies and investors. Bloom Burton's many services
include capital raising, mergers and acquisitions advisory, equity
research, scientific and medical consulting, direct investing,
company creation and incubation. For more information, please visit
www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a
product-pipeline company with a proprietary technology platform
developed at its laboratory facility in France. The company
specializes in the stabilization of carbohydrate molecules, with
the goal of improving compounds' efficacy and safety. Sirona
Biochem's compounds are being developed for both pharmaceutical and
cosmetic marketplaces and are patented as new chemical entities for
maximum commercial protection and revenue potential. Newly
developed compounds are licensed to leading companies around the
world in return for licensing and milestone fees and ongoing
royalty payments. TFChem, Sirona Biochem's wholly-owned French
laboratory is a recipient of multiple French national scientific
awards and a European Union and French government grant. For more
information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
Antonia IssaCommunications ManagerSirona Biochem
Corp.1.604.282.6065aissa@sironabiochem.com
Sirona Biochem (PK) (USOTC:SRBCF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Sirona Biochem (PK) (USOTC:SRBCF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024